








---

# Fabry: A Unique Disease— Uniquely Experienced



# Understanding Fabry disease—a serious, progressive disorder with complex pathology<sup>1</sup>

Fabry disease is an X-linked lysosomal storage disorder.<sup>1</sup> Caused by a deficiency of  $\alpha$ -galactosidase A ( $\alpha$ -Gal A), Fabry disease can have a **devastating impact** on people's lives.<sup>1</sup> Although the disease presents differently in each individual who has it, it can prove to be a significant burden regardless of presentation.<sup>1</sup>

People with Fabry disease may have extremely variable disease courses, ranging from severe, multisystem disease to involvement focused on a single organ system (eg, the kidneys or heart) to relatively mild disease.<sup>1</sup> Heterozygous females can experience a variable presentation, ranging from asymptomatic or mild symptoms to symptoms that are just as severe as those experienced by male patients.<sup>1</sup>

Individuals with Fabry disease may experience a wide variety of symptoms, including the following:

- Acroparesthesia<sup>1</sup>
- Acute pain (“Fabry crises”)<sup>1</sup>
- Hypohidrosis<sup>1</sup>
- Corneal verticillata<sup>2</sup>
- Angiokeratomas<sup>1</sup>
- Gastrointestinal problems, such as abdominal pain and bloating, diarrhea, and early satiety<sup>1,3</sup>
- Renal disease, typically requiring dialysis or transplantation<sup>1</sup>
- Cardiac disease, such as left ventricular hypertrophy, valvular disease, and rhythm disturbances<sup>1</sup>
- Cerebrovascular symptoms, including dizziness, vertigo, transient ischemic attacks, and stroke<sup>1</sup>



---

When Fabry disease is diagnosed, it comes with a long list of possible symptoms and how they can progress. But each individual experiences the disease in his or her own way, making Fabry something that is uniquely experienced.<sup>1</sup>

Because phenotype is not a consistently accurate reflection of genotype in Fabry, gene sequencing can be an important diagnostic tool.<sup>2,4-6</sup> Gene sequencing can enhance our understanding of each patient's unique disease.<sup>5-8</sup>

---



**Genotype alone does not determine disease progression in Fabry disease**—the etiology is complex, and there is a high variability in the manifestation and progression of disease.<sup>4</sup> People with Fabry disease may experience severe symptoms, or seemingly none at all, with a variety of clinical presentations in between.<sup>2</sup> But even when disease presentation is asymptomatic or mild, disease substrate can accumulate, contributing to long-term damage of organs and tissues.<sup>2,9</sup>

Identification of the genetic mutation specific to an individual with Fabry can provide insight into the unique nature of his or her disease.<sup>5-8</sup> If there is suspicion of Fabry disease, gene sequencing is recommended—identifying an individual’s genetic mutation is critical.<sup>2,4-8</sup>

Untreated individuals with Fabry disease may experience a shorter lifespan compared with the general population.<sup>2</sup> Lifespans for people with Fabry disease may be shortened to approximately 50 years for men and 70 for women—a 20- and 10-year reduction, respectively.<sup>2</sup> Cardiovascular disease is the most common cause of death for both men and women.<sup>10</sup>

**Our understanding of Fabry disease continues to grow. We are only just beginning to understand the intricacies of this disorder, but what we do know is that early diagnosis is critical to better outcomes.<sup>1</sup>**

# Fabry disease: a **progressive,** multisystemic, multiorgan disorder<sup>11</sup>

Fabry disease is characterized by multiple organ pathology.<sup>2</sup> Although Fabry disease presents in many different ways—including asymptotically—its progressive nature is consistent irrespective of its presentation.<sup>2</sup>

If Fabry disease is not diagnosed in its early stages, **irreversible organ damage may develop**—although further damage can be managed with a multidisciplinary treatment approach.<sup>1,2</sup>

Organ damage in Fabry disease is caused by the accumulation of globotriaosylceramide (GL-3) and plasma globotriaosylsphingosine (lyso-Gb<sub>3</sub>) in the cells, leading to dysfunction in affected cells.<sup>2,12</sup>

These deposits can potentially affect multiple cell types, including<sup>4</sup>:

- **Endothelial cells: vascular and neurovascular**
- **Cardiomyocytes**
- **Smooth muscle cells**
- **Neurons within the central and peripheral nervous systems**
- **Eccrine sweat glands**
- **Epithelial cells: cornea, lens, airway**
- **Perithelial cells: small intestine, colon, and rectum**
- **Ganglion cells**

## Damage to organ systems can cause a **wide spectrum of symptoms**<sup>4</sup>

ORGAN SYSTEM	PATHOPHYSIOLOGIC PRESENTATION
RENAL	Glomerular sclerosis, tubular atrophy, interstitial fibrosis
CARDIAC	Left ventricular hypertrophy, heart failure, stenosis, atherosclerotic plaques, coronary vasospasm, thrombotic and thromboembolic complications
NEUROLOGIC	Ischemic injury and metabolic failure
DERMATOLOGIC	Weakening of capillary walls and vascular ectasia, narrowing of small blood vessels around sweat glands
OPHTHALMOLOGIC	Streaks in cornea, vasculopathy of conjunctival and retinal vessels, central retinal artery occlusion, reduced tear production
PULMONARY	Airway narrowing, capillary blockage
GASTROINTESTINAL	Narrowing of mesenteric small blood vessels
EAR, NOSE, THROAT	Narrowing or occlusion of cochlear vessels, ischemic auditory neuropathy

# A unique disease presentation necessitates a **unique management strategy**

Fabry disease presents with a high degree of phenotypic heterogeneity—**phenotypic presentation can differ even within families affected by Fabry.**<sup>4</sup> When treating a disorder with the potential to be highly disruptive, it is important to attune any management strategy to the diverse pathologies and the variable severity seen in Fabry disease and to tailor management strategies specifically for each patient.

With a lifestyle-oriented management program, patients can be encouraged to take an active role in their disease management. A personalized program can empower patients to feel that they are **in control of their disease** and to live their lives as they wish—with choice.<sup>13</sup>



# Genetic mutations play a critical role in Fabry disease<sup>7,8</sup>

Fabry is an X-linked disease caused by mutations in the *GLA* gene, which encodes the  $\alpha$ -Gal A enzyme.<sup>1,14</sup> These mutations can cause  $\alpha$ -Gal A, which breaks down GL-3 and plasma lyso-Gb<sub>3</sub> in healthy individuals, to be either absent or deficient.<sup>2</sup> When  $\alpha$ -Gal A is absent or deficient, GL-3 and lyso-Gb<sub>3</sub> accumulate, **leading to damage of cells within affected parts of the individual's body** and causing the various pathologies seen in Fabry disease.<sup>2</sup>

To date, more than 1000 mutations of the *GLA* gene have been associated with Fabry disease.<sup>15</sup> A variety of mutation types can give rise to Fabry disease, such as missense mutations, splicing mutations, small deletions and insertions, and large deletions.<sup>2</sup> Many genetic mutations are specific to individual families affected by Fabry disease, whereas some are more widespread.<sup>1</sup>

Gene sequencing is the only valid tool to diagnose Fabry disease in heterozygous females because in these women, enzyme activity can appear normal.<sup>16</sup> Additionally, in families affected by Fabry, targeted mutational analysis can be used to diagnose at-risk individuals who may not yet exhibit the phenotypic characteristics of the disease.<sup>17</sup>


**Approximately 60% of mutations known to cause Fabry disease are missense mutations.<sup>18,19</sup>**

Missense mutations—caused by the replacement of one amino acid by another—can result in severe disease, as they can cause structural changes that significantly affect the function and stability of the *GLA* gene.<sup>18</sup>

Other types of mutations known to cause Fabry disease include splicing mutations, small deletions and insertions, and large deletions.<sup>1,2</sup>


# The X-linked inheritance pattern of Fabry disease<sup>1</sup>

## INHERITANCE THROUGH AN AFFECTED MOTHER<sup>2</sup>



There is a 50% chance that an affected mother with a heterozygous genotype will pass the defective gene to any of her children.

## INHERITANCE THROUGH AN AFFECTED FATHER<sup>2</sup>



The daughter will inherit the defective gene from her father.

The son will not inherit the defective gene from his father.

- An individual **with** a gene mutation that causes Fabry disease
- An individual **without** a gene mutation that causes Fabry disease

The red X indicates an affected X chromosome.

Males with Fabry disease cannot transmit Fabry to their sons, but will always transmit the disease to their daughters.<sup>2</sup> Females with Fabry disease have a 50% chance of transmitting the disease to their sons and daughters.<sup>2</sup>

# Confirming a patient's genetic mutation may help you to **better understand his or her disease**<sup>5-8</sup>

Manifestations of Fabry disease can differ significantly from individual to individual.<sup>2</sup> Evidence suggests that certain genotypes can result in classic or later onset phenotypes.<sup>20,21</sup> Furthermore, select genotypes have been described as renal or cardiac subtypes (or variants) of disease.<sup>2</sup> In one study, the functional effects of **three different mutations** were studied. Each patient presented in a unique way.<sup>19</sup>

	AGE AT DIAGNOSIS	GENOTYPE	PHENOTYPE
MICHAEL*	42	c.155G>A, p.C52Y	Prior to diagnosis, Michael experienced acroparesthesia, hypohidrosis, and recurrent abdominal pain. Since being diagnosed, he has presented with multiple brain lesions and has experienced loss of mobility and cardiac disease.
ANNE*	49	c.548G>C, p.G183A	Prior to diagnosis, Anne experienced mild hypertension and renal involvement. Anne has also presented with proteinuria (250 mg/h) and developing type 2 diabetes mellitus.
GEORGE*	20	c.647A>G, p.Y216C	Prior to diagnosis, George experienced diffuse angiokeratoma, acroparesthesia, pain, and limb edema. George has also presented with cardiac involvement.

\*Not the patient's actual name.

However, even when family members share **an identical mutation**, their disease presentation may be completely different.<sup>1,22</sup> One study examined the effects of a W226X mutation on two male relatives, showing that although both individuals had an identical mutation, each experienced a unique presentation.<sup>22</sup>

	AGE AT DIAGNOSIS	GENOTYPE	PHENOTYPE
BILL*	18	W226X	Bill was diagnosed with Fabry disease after being evaluated due to severe growth retardation, skeletal dysplasia, and delayed puberty.
MARC*	11	W226X	Marc was diagnosed with Fabry disease after being referred for evaluation due to a family history of Fabry. He experienced acroparesthesia, hypohidrosis, and discomfort. He was previously diagnosed with celiac disease.

\*Not the patient's actual name.




---

Fabry is a unique disease, uniquely experienced. With more than 1000 known mutations,<sup>15</sup> there is no single genotypic cause of Fabry disease.

Regardless of phenotype, Fabry disease is always progressive, even for individuals with mild symptoms.<sup>2</sup>

Gene sequencing can inform diagnosis and lead to a more personalized approach to disease management.<sup>2,5-8,23</sup>

---





**References:** 1. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. *Ann Intern Med.* 2003;138(4):338-346. 2. Germain DP. Fabry disease. *Orphanet J Rare Dis.* 2010;5:30. doi:10.1186/1750-1172-5-30. 3. Keshav S. Gastrointestinal manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, eds. *Fabry Disease: Perspectives From 5 Years of FOS.* Oxford: Oxford PharmaGenesis; 2006: Chapter 28. NCBI website. <http://www.ncbi.nlm.nih.gov/books/NBK11570/>. Accessed December 4, 2015. 4. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. *Genet Med.* 2006;8(9):539-548. 5. Laney DA, Bennett RL, Clarke V, et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. *J Genet Couns.* 2013;22(5):555-564. 6. Desnick RJ, Ioannou YA, Eng CM.  $\alpha$ -galactosidase A deficiency: Fabry disease. In: Valle D, ed. *The Metabolic and Molecular Bases of Inherited Disease.* New York, NY: McGraw Hill, 2001:3733-3774. 7. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. *Medicine (Baltimore).* 2002;81(2):122-138. 8. Anderson LJ, Wyatt KM, Henley W, et al. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. *J Inher Metab Dis.* 2014;37(6):969-978. 9. Namdar M, Gebhard C, Studiger R, et al. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. *PLoS One.* 2012;7(4):e36373. doi:10.1371/journal.pone.0036373. 10. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. *Genet Med.* 2009;11(11):790-796. 11. Mehta A, Beck M, Eyskens F, et al. Fabry disease: a review of current management strategies. *Q J Med.* 2010;103(9):641-659. 12. Rombach SM, Dekker N, Bouwman MG, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. *Biochim Biophys Acta.* 2010;1802(9):741-748. 13. Coulter A, Roberts S, Dixon A. Delivering better services to people with long-term conditions. The King's Fund website. [http://www.kingsfund.org.uk/sites/files/kf/field/field\\_publication\\_file/delivering-better-services-for-people-with-long-term-conditions.pdf](http://www.kingsfund.org.uk/sites/files/kf/field/field_publication_file/delivering-better-services-for-people-with-long-term-conditions.pdf). Accessed January 15, 2016. 14. GLA galactosidase alpha [*Homo sapiens* (human)]. NCBI website. <http://www.ncbi.nlm.nih.gov/gene/2717>. Accessed December 9, 2015. 15. Data on file, Amicus Therapeutics, Inc. 16. Lukas J, Giese A-K, Markoff A, et al. Functional characterisation of alpha-galactosidase A mutations as a basis for a new classification system in Fabry disease. *PLoS Genet.* doi:10.1371/journal.pgen.1003632. 17. Yousef Z, Elliott PM, Cecchi F, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. *Eur Heart J.* 2013;34(11):802-808. 18. Gal A, Schafer E, Rohard I. The genetic basis of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, eds. *Fabry Disease: Perspectives From 5 Years of FOS.* Oxford: Oxford PharmaGenesis; 2006: Chapter 33. NCBI website. <http://www.ncbi.nlm.nih.gov/books/NBK11574/>. Accessed December 4, 2015. 19. Filoni C, Caciotti A, Carraresi L, et al. Functional studies of new GLA gene mutations leading to conformational Fabry disease. *Biochim Biophys Acta.* 2010;1802(2):247-252. 20. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. *J Inher Metab Dis.* 2004;27(3):385-410. 21. El-Abassi R, Singhal D, England JD. Fabry's disease. *J Neurol Sci.* 2014;344(1-2):5-19. 22. Knol IE, Ausems MG, Lindhout D, et al. Different phenotypic expression in relatives with Fabry disease caused by a W226X mutation. *Am J Med Genet.* 1999;82(5):436-439. 23. Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. *Orphanet J Rare Dis.* 2015;10:36. doi:10.1186/s13023-015-0253-6.